Roivant Sciences Ltd. (ROIV) insider trading

By person

15 insiders · 4 transactions

828×

Matthew Gline holds 828 times base salary in stock. $600.90M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $36.31, the price Common Shares was last bought or sold at on the open market here, on 3 Nov 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Eric Venker

President & Immunovant CEO

—

$21.60M (4) scheduled

−$21.60M

999,154

0.1383%

$36.28M

+61.8%

Vivek Ramaswamy

10% owner

—

47,011,612

6.51%

$1.71B

−12.0%

Daniel Allen Gold

Director

—

22,654,981

3.14%

$822.60M

−65.2%

Mayukh Sukhatme

President & CIO

—

18,563,884

2.57%

$674.05M

−17.5%

Matthew Gline

CEO

—

16,549,136

2.29%

$600.90M

−4.7%

Keith S Manchester

Director

—

15,442,623

2.14%

$560.72M

−60.1%

QVT Financial LP entity

Director by Deputization

—

13,689,166

1.90%

$497.05M

−75.6%

Frank Torti

President and Vant Chair

—

13,495,893

1.87%

$490.04M

—

Richard Pulik

CFO

—

269,681

0.0373%

$9.79M

−4.4%

Rakhi Kumar

Chief Accounting Officer

—

162,306

0.0225%

$5.89M

−22.1%

Ilan Oren

Director

—

124,490

0.0172%

$4.52M

+27.2%

James C Momtazee

Director

—

112,265

0.0155%

$4.08M

+19.9%

Jennifer Humes

Chief Accounting Officer

—

106,419

0.0147%

$3.86M

+20,484%

Meghan Fitzgerald

Director

—

41,162

0.0057%

$1.49M

+40.1%

Melissa B, Epperly

Director

—

15,351

0.0021%

$557.39K

−59.6%

Roivant Sciences Ltd.

What the insiders did Scheduled selling only

By person